Full Press Release Details
PRODUCT SALES STATEMENT, FOR
THE PRODUCT SALES MEASURING PERIOD ENDED DECEMBER 31, 2012
As called for under 5.4 of the Contingent Value Rights Agreement by and between Sanofi (formerly known as sanofi-aventis) and American Stock Transfer & Trust Company LLC dated as of
March 30, 2011. All capitalized terms used in the present Product Sales Statement have the respective meanings ascribed to them therein. Amounts set forth herein are not necessarily indicative of results that will be achieved in subsequent
Product Sales Measuring Periods.
Sales data to be provided prior to fulfilment of Product Sales Milestone #1:
| Market | Q4 2012 | Q3 2012 | Q2 2012 | Q1 2012 | ||||||||||||||||||||||||||||||||||||||||||||
| (I) | (II) | X- rate | (I) | (II) | X- rate | (I) | (II) | X- rate | (I) | (II) | X- rate | |||||||||||||||||||||||||||||||||||||
| Major Markets | ||||||||||||||||||||||||||||||||||||||||||||||||
| USA | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | ||||||||||||||||||||||||||||||||||||
| UK | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | ||||||||||||||||||||||||||||||||||||
| France | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | ||||||||||||||||||||||||||||||||||||
| Germany | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | ||||||||||||||||||||||||||||||||||||
| Italy | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | ||||||||||||||||||||||||||||||||||||
| Spain | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | ||||||||||||||||||||||||||||||||||||
| Subtotal | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | ||||||||||||||||||||||||||||||||||||
| All other | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | 0 | 0 | N/A | ||||||||||||||||||||||||||||||||||||
| Exclusions | ||||||||||||||||||||||||||||||||||||||||||||||||
| Oncology (1) | 0 | N/A | N/A | 12.4 | N/A | N/A | 18.7 | N/A | N/A | 21.4 | N/A | N/A | ||||||||||||||||||||||||||||||||||||
| Transplant Indications* | ** | N/A | N/A | 1.0 | (2) | N/A | N/A | 1.1 | N/A | N/A | 1.0 | N/A | N/A |
| (I): | Aggregate gross amount invoiced by the Company, its Affiliates and its licensees for sales of the Product by the Company, its Affiliates and licensees of the Company and its Affiliates to third parties, in millions of United States dollars. | |
| (II): | Product Sales, in millions of United States dollars. | |
| X-rate: | Exchange rates used for conversion of the specified Major Market s foreign currency into United States dollars for the quarter indicated. Exchange rates for other markets will be provided to the extent there are sales invoiced in currencies other than the United States dollar. | |
| *: | Note that amounts appearing in this line are a subset of the amounts appearing in the Oncology line, above, provided for information purposes and calculated by reference to relevant data compiled by the UNOS (United Network for Organ Sharing). | |
| **: | During the period under review, there were no Transplant Indication stock keeping units (SKUs) recorded. UNOS data specifying Transplant Indication usage for the specified period is not available as of the date of this Statement. | |
| N/A: | Not applicable. | |
| (1): | The Company is in the process of ceasing the commercialization of Campath on a global basis. In the countries where the sales have ceased, Campath is being made available to patients at no cost through a patient access/distribution program. Previously sold product amounting to 0.3 million of United States dollars were returned to the Company during the quarter. | |
| (2): | Preliminary figure. |
Do Product Sales in the Product Sales Measuring Period ended December 31, 2012 include Product Sales of a
Combination Product?
Has any Product Sales Milestone been achieved during the Product Sales Measuring Period ended
After due inquiry and to the best of the knowledge and belief of the undersigned,
the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.
| Sanofi | ||
| By: | /s/ J r me Contamine | |
| Name: | J r me Contamine | |
| Title: | Executive Vice President, Chief Financial Officer | |
| Date: February 7, 2013 |